Axsome Therapeutics beats revenue expectations but posts wider loss as commercialization and pipeline spending increase.
Stock Earnings Results
May 4, 2026
Table of Contents
May 4, 2026
Axsome Therapeutics, Inc. (NASDAQ: AXSM) reported first-quarter 2026 revenue above expectations, but posted a wider-than-expected loss as spending increased across commercialization and pipeline development.
Axsome is a biopharmaceutical company focused on treatments for central nervous system disorders, including depression, migraine, narcolepsy, Alzheimer’s disease agitation, schizophrenia, and Tourette syndrome.
The company reported a loss of $1.26 per share, wider than estimates for a loss of $0.85, representing a negative 48.2% earnings surprise. Revenue came in at $191.20 million, above estimates of $189.24 million, with total net product revenue increasing 57% year-over-year.
Axsome generated $191.2 million in first-quarter net product revenue, up from $121.5 million in the prior-year period.
AUVELITY remained the largest contributor, with net product sales of $153.2 million, up 59% year-over-year. SUNOSI revenue increased 34% to $33.9 million, while SYMBRAVO contributed $4.1 million in the quarter.
The main issue was cost growth.
Research and development expenses rose to $52.7 million from $44.8 million, partly due to a one-time acquisition-related expense. Selling, general, and administrative expenses increased to $185.0 million from $120.8 million, driven by pre-launch work for AUVELITY in Alzheimer’s disease agitation, direct-to-consumer advertising, and commercialization activity for SYMBRAVO.
AUVELITY was approved for the treatment of agitation associated with dementia due to Alzheimer’s disease.
That approval expands the product’s addressable market and gives Axsome another commercial growth driver, but it also requires investment in launch and market development.
Axsome submitted an NDA for AXS-12 for cataplexy in narcolepsy and added AXS-20, a pre-Phase 3 PDE10A inhibitor for schizophrenia and Tourette syndrome, to its pipeline.
The company now has three marketed medicines approved across four CNS conditions and a broader pipeline targeting several psychiatric and neurological disorders.
Investors are likely to watch whether Axsome can convert product revenue growth into profitability.
The key areas are:
Axsome’s quarter shows the tradeoff biotech investors often face between commercial growth and spending pressure.
Revenue growth remains strong, and AUVELITY’s expanded approval adds upside. But the wider-than-expected loss shows that commercialization costs are still absorbing much of the growth.
Platforms like LevelFields track earnings results, FDA approvals, layoffs, activist investor stake, and more helping investors identify when biotech earnings include both growth catalysts and profitability risks.
Join LevelFields now to be the first to know about events that affect stock prices and uncover unique investment opportunities. Choose from events, view price reactions, and set event alerts with our AI-powered platform. Don't miss out on daily opportunities from 6,300 companies monitored 24/7. Act on facts, not opinions, and let LevelFields help you become a better investor.
AI scans for events proven to impact stock prices, so you don't have to.
LEARN MORE